Key facts
- Kvantify’s last known valuation is $21.4M (Jul 2024).
- It has raised $70.4M; the latest was Early Stage VC ($52.2M) in Mar 2026.
- Notable investors include European Innovation Council, Denmark's Export and Investment Fund, Nordic Mentor Network For Entrepreneurship, QAI Ventures, Future Five — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Kvantify
- ·The full record, as it builds
Funding rounds
No funding rounds for Kvantify are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kvantify
Developer of a healthcare platform designed to solve computational challenges in drug discovery. The company's platform facilitates computational drug technology to improve the quality of compounds tested in the lab by leveraging proprietary, accurate physics-based methods, enabling life sciences companies to accelerate small molecule research and deliver actionable results that make a difference.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2022
- Employees
- 60
- Website
- kvantify.com/
- Ownership
- Privately Held (backing)
Kvantify doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kvantify shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kvantify in its N-PORT filings yet. We sweep new filings monthly.